Photo by finnnyc from unsplash
Evidence for neoadjuvant therapy (NAT) in extrahepatic cholangiocarcinoma (eCCA) is limited. Our objectives were to: (1) characterize treatment trends, (2) identify factors associated with receipt of NAT, and (3) evaluate… Click to show full abstract
Evidence for neoadjuvant therapy (NAT) in extrahepatic cholangiocarcinoma (eCCA) is limited. Our objectives were to: (1) characterize treatment trends, (2) identify factors associated with receipt of NAT, and (3) evaluate associations between NAT and postoperative outcomes.
Keywords:
postoperative outcomes;
neoadjuvant therapy;
therapy use;
extrahepatic cholangiocarcinoma
Journal Title: Journal of Surgical Oncology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Surgical Oncology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!